Rocket Pharmaceuticals (RCKT) Misses Q2 EPS by 2c

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q2 EPS of ($0.74), $0.02 worse than the analyst estimate of ($0.72).

For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Canadian trade officials to meet U.S. counterparts in Washington Monday
• EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies